GentleGen's G-Lab fully automated platform enables efficient delivery from gene synthesis to antibody expression within 7-10 days

Release time:2026-06-25

In the biopharmaceutical field, the efficiency and quality of antibody R&D directly determine project advancement speed and market competitiveness. Currently, the industry generally faces pain points such as fragmented processes, lengthy cycles, high costs, and inconsistent quality control standards, which severely restrict the R&D progress of innovative antibodies. Relying on its self-built GentSynExp 3.0 G-Lab fully automated gene antibody platform, GentleGen has built a one-stop solution covering gene design, synthesis, validation, protein expression, and antibody development. With advantages in automation, high throughput, and high precision, it provides efficient, stable, and cost-effective R&D support for the industry.

Full-process automation empowerment, breaking through R&D efficiency bottlenecks

GentleGen's G-Lab 3.0 platform innovatively adopts a "dark factory" modular production model, integrating automated hardware systems, AI algorithms, and information management platforms to achieve full-chain unmanned production from genetic design to plasmid delivery, with human error rates approaching zero. The platform's core advantages are reflected in:

Rapid delivery cycle: Relying on 7×24/7 uninterrupted synthesis capability, the fastest delivery time from gene synthesis to antibody supernatant is only 7-10 days, shortening the industry average cycle of 2-4 weeks by over 50%; Cloning vector delivery takes as little as 72 hours, with transfection-grade plasmid preparation completed in just 3 working days.

Full-process technical coverage: Covers key steps such as automated gene PCR assembly, plasmid extraction, gel recapping and purification, Sanger sequencing validation, monoclonal selection, and protein expression, seamlessly connecting the entire antibody development process without multi-platform collaboration, significantly reducing communication and time costs.

High-throughput production capability: Processing 3000+ samples in a single pass and exceeding 5000+ in a single day, efficiently meeting the batch screening needs of biopharmaceutical companies and research institutions, suitable for large-scale production scenarios from milligram to kilogram scale.

Core technology breakthroughs to build dual advantages in quality and cost

1. Technical barriers: Overcoming the challenges of complex sequence synthesis

The platform independently develops intelligent codon optimization algorithms and complex sequence assembly technologies, successfully overcoming synthesis bottlenecks such as high GC/AT content and repeat sequences. It can efficiently synthesize single genes over 10kb in fragments, with a first-time synthesis success rate as high as 99%, sequence accuracy of 99.9%, and superhelical plasmid proportion exceeding 90%, meeting the demanding application requirements for transfecting mammalian cells, virus packaging, and mRNA preparation.

2. Quality Control System: Multi-dimensional assurance of product stability

Establish strict quality control standards throughout the entire process, using multidimensional methods such as HPLC-SEC testing, SDS-PAGE analysis, enzyme digestion validation, and endotoxin testing to ensure uniform and stable product quality:

Plasmid products: OD260/280 values controlled between 1.8-2.0, RNA residual gel electrophoresis not visible, E. coli genome residue below 15% of plasmid bands, endotoxin content ≤0.1 EU/μg, 48-hour sterile detection showed no growth.

Antibody product: Purity (HPLC-SEC/SDS-Page) ≥95%, endotoxin ≤ 1 EU/mg; expressing cells use the Expi293/CHO system, delivered at a concentration ≥ 1 mg/ml, stored in PBS to ensure activity and stability.

3. Cost advantage: Large-scale production reduces unit costs

Reducing labor and reagent consumption through automated production, combined with a modular and replicable factory model, achieves cost optimization:

IgG monoclonal antibody gene synthesis service: 259 RMB per cell (minimum order of 30), each pair comes with 800 μl of antibody supernatant, which can be directly used for functional validation, affinity evaluation, and other downstream experiments, eliminating the purification step.

VHH nanobody gene synthesis service: 129 RMB per cell (minimum order of 50), with a complimentary 800μl antibody supernatant, significantly reducing early screening costs.

Full-chain service coverage spans the entire antibody R&D cycle

GentleGen's service system covers the entire antibody process from discovery to optimization, adapting to hybridomas, phage display, transgenic mice, single B cell screening, and other technical pathways. Core services include:

Antibody library synthesis (phage display technology pathway);

Automated first/second-generation sequencing sequence screening; Antibody sequence synthesis and transient expression (AB leads screening);

Gene synthesis and mutation synthesis (humanized modification, affinity maturation, Fc engineering optimization);

Customized services including recombinant antibody heavy and light chain plasmid preparation, one-step antibody purification, endotoxin testing, and more.

GentleGen is committed to providing professional and efficient gene and antibody technology services to global biopharmaceutical R&D institutions. For detailed information about these services, please email marketing@gentlegen.com.

Contact Sales

Contact Sales Assistant

Contact PM